Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.
Capitol Hill: With money tight, support for 2015 goal is symbolic.
Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.
NCI selects nanotech centers for funding.
Trending Stories
- “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
- How City of Hope is turning microbiome science into better cancer care
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members









